IL13 Ralpha2 CAR-T

N/A

Report date: 2025/03/20 15:57:06

Base Information

Drug NameIL13 Ralpha2 CAR-T
Drug Alias Nameanti- IL-13Ralpha2 CAR T-cell therapy (Tmunity)anti- IL-13Ralpha2 CAR T-cell therapy (Kite Pharma)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionInterleukin-13 receptor subunit alpha-2 modulators
TargetsInterleukin-13 receptor subunit alpha-2
Therapy Area/IndicationsGlioblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTmunity Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesKite Pharma Inc
Inactive CompaniesTmunity Therapeutics Inc
Active IndicationsGlioblastoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A